UNSPSC 51162001: Amobarbital/ephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.

UNSPSC 51162001 Amobarbital/ephedrine is a Commodity code that represents pharmaceutical products, though recent state and local solicitations under this code show activity focused on broader pharmacy services, naloxone procurement, and generic pharmaceutical supply agreements rather than the specific amobarbital/ephedrine compound. State and local governments are buying pharmacy management services, emergency-response pharmaceuticals (naloxone), and generic multisource pharmaceutical supply through cooperative purchasing arrangements. Issuing bodies include county health departments (Seminole County, Florida; Hall County, Georgia), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across multiple jurisdictions including Oregon). The work spans on-site pharmacy service provision at government health clinics, direct procurement of emergency medications for community health initiatives, and participation in cooperative pharmaceutical supply frameworks that aggregate demand across state and local entities.

Recent activity concentrates in Florida, Georgia, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, response deadline July 26, 2023. Hall County, Georgia issued RFQ/P #47-010 in May 2026 for on-site pharmacy services at the Hall County Government Family Health Center Clinic serving approximately 3,005 eligible individuals, with sealed proposals due June 4, 2026 under an 80/20 technical-to-cost scoring structure and a one-year initial term with four optional renewal years. Texas HHS issued RFI HHS0017013 in April 2026 to solicit vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, functioning as preliminary market intelligence to inform future procurement strategy. Minnesota's MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 for generic multisource pharmaceuticals and OTC products with proposals due March 26, 2026, serving state and local government facilities with evaluation weighting 75 percent on price competitiveness, 10 percent on fixed pricing, and 15 percent on administrative and technical factors, with awarded vendors effective July 1, 2026.